MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
886 produits trouvés pour "MAPK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Formule :C31H36ClFN6O2Couleur et forme :SolidMasse moléculaire :579.11Rho GTPase inhibitor 1
CAS :<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Formule :C18H16N2OCouleur et forme :SolidMasse moléculaire :276.33G-479
CAS :<p>G-479, a potent MEK inhibitor and improved analogue of GDC-0623, has distributed polarity enhancing bioactivity.</p>Formule :C16H15FIN5O4Couleur et forme :SolidMasse moléculaire :487.22MEK4 inhibitor-2
CAS :<p>MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.</p>Formule :C20H15FN4O3SCouleur et forme :SolidMasse moléculaire :410.42XMU-MP-9
CAS :<p>XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.</p>Formule :C19H13ClFN3OSCouleur et forme :SolidMasse moléculaire :385.84PAT-IN-1
CAS :<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Formule :C45H68N4OCouleur et forme :SolidMasse moléculaire :681.05EBI-907
CAS :<p>EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.</p>Formule :C23H21ClF2N4O3SCouleur et forme :SolidMasse moléculaire :506.95SOS1 activator 2
CAS :<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Formule :C26H28ClFN6Couleur et forme :SolidMasse moléculaire :478.992KRAS inhibitor-21
CAS :<p>KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.</p>Formule :C33H41N5O3Couleur et forme :SolidMasse moléculaire :555.71p38 Kinase inhibitor 8
CAS :<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>Formule :C22H21FN6O2Couleur et forme :SolidMasse moléculaire :420.44KRASG12D-IN-3-d3
CAS :KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.Formule :C31H27D3ClF6N7O2Couleur et forme :SoildMasse moléculaire :685.08L 739749
CAS :<p>L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.</p>Formule :C24H41N3O6S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :531.73LSN3074753
CAS :<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Formule :C24H30FN5O2Couleur et forme :SolidMasse moléculaire :439.53p38α inhibitor 8
CAS :<p>p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.</p>Formule :C17H13FN6Couleur et forme :SolidMasse moléculaire :320.324p38 Kinase inhibitor 7
CAS :<p>p38 Kinase inhibitor 7 (Comp:XXXIX) is an inhibitor of p38α, with an IC50 value of 5.25 nM. It also effectively suppresses TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM.</p>Formule :C22H25FN6OCouleur et forme :SolidMasse moléculaire :408.472Fulzerasib
CAS :<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Formule :C32H30ClFN6O4Degré de pureté :98.04%Couleur et forme :SolidMasse moléculaire :617.07p38 MAP Kinase-IN-1
CAS :<p>p38 MAP Kinase-IN-1 (Compound 4) is an inhibitor of p38, suitable for studies related to inflammation and autoimmune responses.</p>Formule :C20H19FN6OCouleur et forme :SolidMasse moléculaire :378.403Coelogin
CAS :<p>Coelogin is an orally effective bone-protective agent that activates ER-Erk and Akt-dependent signaling pathways, thereby stimulating osteoblast differentiation. It is utilized in osteoporosis research.</p>Formule :C17H16O5Couleur et forme :SolidMasse moléculaire :300.31Casein kinase 1δ-IN-27
CAS :<p>Casein kinase1δ-IN-27 (Compound 8) is an inhibitor of casein kinase 1 (CK1), effectively inhibiting CK1α, CK1δ, CK1ε, and p38α with IC50 values of 22, 16.5, 9.41, and 14.8 nM, respectively. It also suppresses DUX4 expression, with an IC50 of 10 nM.</p>Formule :C21H19FN6Couleur et forme :SolidMasse moléculaire :374.414JNK-IN-19
CAS :<p>JNK-IN-19 (Compound Q8) is an inhibitor of c-Jun N-terminal kinase, utilized for the treatment and/or prevention of injuries prior to, during, or following surgery.</p>Formule :C22H24F3N6Na2O6PCouleur et forme :SolidMasse moléculaire :602.41
